Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Werewolf Therapeutics Inc (HOWL)

Werewolf Therapeutics Inc (HOWL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,994
  • Shares Outstanding, K 43,455
  • Annual Sales, $ 19,940 K
  • Annual Income, $ -37,370 K
  • 60-Month Beta 0.46
  • Price/Sales 4.49
  • Price/Cash Flow N/A
  • Price/Book 0.79
Trade HOWL with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 109.53%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 838.04% on 06/20/24
  • IV Low 0.00% on 07/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,023
  • Open Int (30-Day) 1,911

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.38
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.43
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -171.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +4.08%
on 06/25/24
3.69 -44.79%
on 06/07/24
-1.55 (-43.18%)
since 06/05/24
3-Month
1.96 +4.08%
on 06/25/24
6.89 -70.39%
on 04/29/24
-3.88 (-65.54%)
since 04/05/24
52-Week
1.57 +29.65%
on 10/24/23
8.19 -75.10%
on 02/26/24
-1.09 (-34.82%)
since 07/05/23

Most Recent Stories

More News
RSI Oversold: 2 Stocks (HOWL, WKHS) Potentially Signaling a Contrarian Buy

Sometimes equities that have been pushed too far down are at risk of surprisingly bouncing back.

HOWL : 2.01 (-6.07%)
WKHS : 1.3600 (+0.37%)
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting

WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights

-Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program-...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...

HOWL : 2.01 (-6.07%)
RSI Alert: Werewolf Therapeutics (HOWL) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics is Now Oversold (HOWL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

HOWL : 2.01 (-6.07%)
Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...

HOWL : 2.01 (-6.07%)

Business Summary

Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.55
2nd Resistance Point 2.41
1st Resistance Point 2.28
Last Price 2.01
1st Support Level 2.01
2nd Support Level 1.87
3rd Support Level 1.74

See More

52-Week High 8.19
Fibonacci 61.8% 5.66
Fibonacci 50% 4.88
Fibonacci 38.2% 4.10
Last Price 2.01
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar